Source comparison
CJC-1295 no DAC & Ipamorelin Alternatives 2026 Best: Peptide Comparison
The table below compares the most effective CJC-1295 no DAC & Ipamorelin alternatives available in 2026 across key research parameters. | Peptide | Mechanism | Half-Life | Typical Research Dose | Peak GH Increase vs Baseline | Desensitization Timeline | Profes
This comparison does not assign a generated winner or score.
- The table below compares the most effective CJC-1295 no DAC & Ipamorelin alternatives available in 2026 across key research parameters.
- | Peptide | Mechanism | Half-Life | Typical Research Dose | Peak GH Increase vs Baseline | Desensitization Timeline | Professional Assessment ||—|—|—|—|—|—|| Hexarelin | GHS-R1a agonist (ghrelin mimetic) | ~70 minutes | 100–200mcg 2–3x/day | 300–500% | 3–4 weeks continuous use | Strongest GH pulses of any synthetic ghrelin analog. Requires strict cycling (4 weeks on, 4 off) to prevent tachyphylaxis. Ideal for short, intense research phases targeting maximal anabolic signaling. || Tesamorelin | GHRH analog | 26–38 minutes | 1–2mg once daily | 200–350% | 16–24 weeks | FDA-approved for HIV-associated lipodystrophy. Superior visceral fat reduction vs modified GRF. Maintains efficacy longer than CJC-1295 no DAC due to optimized GHRH receptor selectivity. || MK-677 (Ibutamoren) | Oral GHS-R1a agonist | ~24 hours | 10–25mg once daily | 60–90% sustained | No observed desensitization over 2 years | Eliminates injection frequency. Provides 24-hour GH/IGF-1 elevation rather than pulsatile release